Immuno-chemo combo takes on hard-to-treat lymphoma
NCT ID NCT05221645
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard R-ICE chemotherapy can help people with diffuse large B-cell lymphoma that has returned or not responded to earlier treatment. About 65 adults will take part. The main goal is to see how many are alive and free of lymphoma one year later.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oxford Cancer & Haematology Centre, The Churchill Hospital
Headington, Oxford, OX3 7LE, United Kingdom
-
The Beatson West of Scotland Cancer Centre
Glasgow, Glasgow, G12 0YN, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the key to better CAR-T therapy lie in the gut?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope
- New drug combo aims to tame aggressive lymphoma in frail patients
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Double-Pronged immune cells take aim at stubborn blood cancers